Navigation Links
Regeneron Announces June 2012 Investor Conference Presentations
Date:5/30/2012

TARRYTOWN, N.Y., May 30, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:

  • Goldman Sachs Global Healthcare Conference 2012 at 7:00 p.m. Eastern Time (4:00 p.m. Pacific Time) on Tuesday, June 5, 2012
  • Jefferies 2012 Global Healthcare Conference at 10:30 a.m. Eastern Time on Thursday, June 7, 2012
  • The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  Archived versions of the presentations will be available for thirty days after the live webcasts. 

    Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection for Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.   A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.  Earlier-stage clinical programs are underway with nine additional monoclonal antibodies.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information: Mani
    '/>"/>

    SOURCE Regeneron Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
    2. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
    3. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
    4. Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
    5. Regeneron Announces February 2012 Investor Conference Presentations
    6. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
    7. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
    8. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
    9. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
    10. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
    11. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:3/27/2015)... 2015 As of February, InControl Medical, ... for women. "Shipping thousands of our ... is the hundreds of letters, emails and phone ... been positively impacted by our technology," said ... InControl recently released Apex, an over-the-counter solution for ...
    (Date:3/27/2015)...   Hospira, Inc. (NYSE: HSP ... world,s leading provider of injectable drugs and infusion ... of biosimilarity of its proposed biosimilar, Epoetin Hospira, ... conditionally approved name of RETACRIT™, compared to the ... data were presented at the National Kidney Foundation ...
    (Date:3/27/2015)... 27, 2015  Johnson & Johnson (NYSE: JNJ ) ... (Eastern Time) on Thursday, April 23, 2015, from the State ... Investors and other interested parties may access the live ... at www.jnj.com and clicking on the webcast icon. ... be made available a few hours after the live meeting ...
    Breaking Medicine Technology:InControl Medical Surpasses 40,000 Shipments Of Incontinence Devices For Women 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
    ... Inc. (Nasdaq: MYL ) CEO Heather Bresch today ... Committee at a hearing hosted by the subcommittee on Health ... Fees and Further Examination of Drug Shortages." In ... of mind in knowing that every prescription, brand or generic, ...
    ... Mass., Feb. 9, 2012 Syndax Pharmaceuticals, ... that scientists at Roswell Park Cancer Institute have ... inhibitor of class I histone deacetylases, has novel ... of cancer immunotherapies in models of renal and ...
    Cached Medicine Technology:Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 2Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 3Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers 4Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models 2Syndax Pharmaceuticals Announces Entinostat Enhanced Activity of Cancer Immunotherapies in Renal and Prostate Cancer Models 3
    (Date:3/28/2015)... 28, 2015 How best to treat ... field in orthopaedic medicine. While diagnostic hip injections are ... the pain etiology, research presented today at the American ... Day suggests that pain relief from this diagnostic injection ... , “Our study looked to assess if the ...
    (Date:3/28/2015)... NC (PRWEB) March 28, 2015 Genomic ... with peritoneal mesothelioma, revealing, for the first time, key ... Click here to read the newly posted story ... at the University of British Columbia, the British Columbia ... genome mapping to reveal underlying molecular alterations and mutations ...
    (Date:3/28/2015)... 2015 Aureus Medical Group (web: ... physical therapy jobs, has announced that it will ... Therapy Association Annual Conference to be held April ... in Columbus, OH. , The OPTA Annual ... with products and services. , Representatives from ...
    (Date:3/28/2015)... Viejo, California (PRWEB) March 28, 2015 ... announced a new overlay entitled Scratches 5K from Pixel ... grungy scratch effects to any media inside Final Cut ... Studios. “StoryBoard Corporate saves time and is an effective ... media using FCPX Overlay Scratches 5K's intuitive grunge overlays. ...
    (Date:3/28/2015)... CA (PRWEB) March 28, 2015 ... specialists , this week released a report about the ... symptoms of asthma sufferers, and according to recent medical ... , According to the Environmental Protection Agency, people ... asthmatic reactions. Breathing in mold may trigger asthma attacks ...
    Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3
    ... , NEW YORK, Aug. 14 MS ... conducted by AstraZeneca, found that while most patients with asthma ... act accordingly. , , "This finding ... asthma and the necessary steps people should take to achieve ...
    ... ... present a technology and admissions educational session for THCA members , ... Atlanta, GA (PRWEB) August 14, 2009 ... providers, announced today that it will present a session at the Tennessee Health Care ...
    ... ... collision avoidance method used in uncontrolled areas, risks inherent in such situations , ... San Mateo, CA (Lexis Nexis) August 14, ... August 8th, in which nine people were killed when a small aircraft collided in midair ...
    ... , SACRAMENTO, Calif., Aug. 13 The ... million to the Healthy Families Program today to cover health care costs ... due to the state,s fiscal crisis. The funding, approved at a special ... 0-5 through June 2010. , , "In the current ...
    ... ... of Sexual Health in His New Book ,Ultimate Sexual Health & Performance, , ... Los Angeles, California (Vocus) August 13, 2009 ... his book ,Ultimate Sexual Health & Performance., Bringing over 35 years of research and ...
    ... , , JACKSON, Miss., Aug. 13 ... benefits for speech therapy services, The Mississippi School Boards Association and ... the new Medicaid claiming policy for the coming school year . ... by school providers, which are in fact still claimable. Specifically, ...
    Cached Medicine News:Health News:Keeping Asthma Under Control 2Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 2Health News:Patient Placement Systems Presents a Session at the THCA 2009 Annual Convention 3Health News:Midair Collision over Hudson Provides Tragic Reminder that Airplanes and Helicopters Don't Mix Well, According to Aviation Law Expert 2Health News:First 5 California Approves $81.4 Million Contribution to Help Restore Healthy Families Program's Viability 2Health News:Definitive Sexual Health Book Released 2Health News:Definitive Sexual Health Book Released 3Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 2Health News:Mississippi School Boards Association and Accelify Attain Clarity on New Medicaid Claiming Policy for Coming School Year 3
    ... control is designed for monitoring human urine ... routine and stat testing and meets CLIA ... are included for most frequently tested analytes. ... chemistry analyzers including: Aeroset, AU Series, Cobas, ...
    ... control validates urine dipstick readings by applying ... a plastic dropper tip designed for easy ... is the addition of creatinine and microalbumin. ... qualitative results for hCG for early pregnancy ...
    ... quanTtest human protein standards are available in ... and 200 mg/dL and are packaged in ... ready-to-use, requiring no reconstitution or dilution and ... purified human albumin and human globulin at ...
    ... is a completely new concept ... use of optic technology for ... applying touch-less vibration system (Patent ... ergonomic user friendly, novel design ...
    Medicine Products: